SS Innovations International (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, using the SSi Mantra 3.0 surgical robotic system. The program commenced with a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development, highlighted in a recent company video, represents a significant step in bringing advanced robotic cardiac care to Sri Lanka and underscores the growing adoption of the SSi Mantra system in new markets.
The introduction of robotic cardiac surgery in Sri Lanka is important because it expands access to minimally invasive techniques that can lead to smaller incisions, reduced pain, and faster recovery times for patients. By supporting the launch of this program, SS Innovations is not only demonstrating the clinical versatility of its SSi Mantra 3.0 system but also positioning itself as a key player in the global robotic surgery market. Kings Hospital has completed more than 25 robotic procedures in just three weeks, according to the company video, indicating rapid adoption and confidence in the technology.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, reflecting its expanding international presence. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These metrics suggest that the SSi Mantra system is gaining traction among surgeons and hospitals, which is critical for driving recurring revenue and long-term growth.
Beyond geographic expansion, SS Innovations is pursuing regulatory milestones that could further accelerate adoption. The company is seeking U.S. Food and Drug Administration (FDA) clearance and European CE marking for the SSi Mantra system. Achieving these certifications would allow SS Innovations to enter two of the largest and most lucrative medical device markets in the world, significantly broadening its addressable market and enhancing its competitive position against established players in the robotic surgery field.
The launch in Sri Lanka also has implications for the broader healthcare landscape in South Asia, where access to advanced surgical technologies has historically been limited. By introducing robotic cardiac surgery, Kings Hospital and SS Innovations are setting a precedent that could encourage other hospitals in the region to invest in similar programs. This could lead to improved patient outcomes and help stem the flow of patients traveling abroad for advanced cardiac care.
For investors, the news signals execution on SS Innovations' strategy to penetrate new geographies and clinical applications. The company's ability to support the launch of a new robotic cardiac program in a relatively short timeframe demonstrates operational capability and the potential for further expansion. As SS Innovations continues to pursue FDA and CE mark approvals, the successful deployment of its technology in diverse markets like Sri Lanka could serve as a reference point for regulators and hospital administrators evaluating the system.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published, please see: https://IBN.ai/Disclaimer.
